Quest Diagnostics Incorporated (DGX)

Quest Diagnostics stock has experienced notable events in the past six months. As of May 7, 2026, the stock was up 8.08% over the past 12 months, with a 52-week range between $164.65 and $213.50, closing at $190.84 on May 7, 2026. The company priced a $500 million senior notes issue. Analysts have upgraded their outlook for DGX amid strong first-quarter growth, and the company reported strong Q1 2026 financial results, leading to raised revenue and EPS guidance for the full year 2026. In Q1 2026, Quest Diagnostics saw a 9.2% year-over-year revenue increase and a 13% EPS growth, with total requisition volume increasing by 10.9%.

Demand for Quest Diagnostics' services is influenced by steady demand for diagnostic checkups, especially among older Americans, and an increase in demand for specialized tests like liquid biopsies. There is also a growing consumer preference for convenient healthcare solutions, including point-of-care and direct-to-consumer testing, indicating consistent underlying demand with growth in specialized and consumer-driven testing.

Quest Diagnostics, Inc. is a leading American clinical laboratory and a Fortune 500 company in the healthcare sector, providing a range of diagnostic testing, information, and services. Its offerings include routine clinical testing, anatomic pathology services, molecular and genomic diagnostics, infectious disease testing, and specialized esoteric testing. The company also provides employment and court-ordered drug testing, along with health information solutions to integrate lab data into healthcare workflows, with a mission to deliver reliable and accessible diagnostic solutions.

Quest Diagnostics is headquartered in Secaucus, New Jersey, and has operations in the United States, Puerto Rico, Mexico, India, and Ireland. Its services are available across six continents and over 130 countries. In the U.S., it operates a national network of laboratories in major metropolitan areas and around 2,000 patient service centers, collaborating with international diagnostic laboratories, hospitals, and clinics globally.

Quest Diagnostics has maintained a strong brand reputation, being named to Fortune's "World's Most Admired Companies" list for 12 consecutive years, including in 2024 and 2026. It has also been recognized for inclusion & diversity and environmental sustainability. In 2022, Fast Company included Quest Diagnostics in its "Brands That Matter" list for its Quest for Health Equity initiative. However, in 2018, the company was linked to inaccuracies in cervical smear tests for Ireland's CervicalCheck program, leading to lawsuits and a government inquiry.

Quest Diagnostics is predominantly owned by institutional shareholders, holding 95.88% of the stock. The largest shareholder is Vanguard Group Inc. with 13.00% of the company. Other major institutional owners include BlackRock Inc., Price T Rowe Associates Inc, State Street Corp, Jpmorgan Chase & Co, Boston Partners, Geode Capital Management LLC, Morgan Stanley, Victory Capital Management Inc, and Dimensional Fund Advisors LP. Insiders own 1.82% of the stock, while retail investors hold 2.30%.